Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Updated results from BELLINI: venetoclax with bortezomib/dexamethasone

Shaji Kumar, MD, Mayo Clinic, Rochester, MN, outlines the updated results from the BELLINI trial (NCT02755597), a Phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory (R/R) multiple myeloma (MM). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).